Diferencia entre revisiones de «Butorphanol»
(Created page with "==Administration== *Type: synthetic mixed agonist-antagonist opioid *Dosage Forms: *Routes of Administration: IV, IN *Common Trade Names: ==Adult Dosing== *0.5-2mg IV, I...") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 2 ediciones intermedias del mismo usuario) | |||
| Línea 48: | Línea 48: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Butorphanol]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revisión actual - 21:55 20 mar 2026
Administration
- Type: synthetic mixed agonist-antagonist opioid
- Dosage Forms:
- Routes of Administration: IV, IN
- Common Trade Names:
Adult Dosing
- 0.5-2mg IV, IM, or IN q3h prn
Pediatric Dosing
Special Populations
Pregnancy Rating
- Category C
Lactation risk
- Infant risk cannot be ruled out
Renal Dosing
- Reduce dose (0.5-1mg)
Hepatic Dosing
- Reduce dose (0.5-1mg)
Contraindications
- Allergy to class/drug
- Significant respiratory depression
- Acute or severe asthma if unmonitored setting
- Known or suspected SBO or ileus
Adverse Reactions
Serious
- Respiratory depression
Common
- Nausea/vomiting
- Sedation/somnolence, Dizziness, insomnia
- Nasal congestion (long term use of IN)
Pharmacology
- Half-life: 4-6h in healthy patients, 10-17h inhepatic or renal impairment
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Mixed agonist-antagonist analgesic, kappa-opioid receptor agonist, low intrinsic activity at mu-opioid receptor
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 0.5-2.0 mg IV; average 2 mg q3-4h | Step 3 - Severe pain (mixed agonist-antagonist) | IV | Adult |